Wells Fargo & Company Sorrento Therapeutics, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.74 - $1.83 $207,786 - $513,851	-280,793 Reduced 21.26%	1,039,799 $925,000
Q3 2022 Nov 14, 2022	BUY	$1.51 - $2.88 $323,194 - $616,423	214,036 Added 19.34%	1,320,592 $2.07 Million
Q2 2022 Aug 12, 2022	SELL	$1.24 - $2.33 $288,461 - $542,027	-232,630 Reduced 17.37%	1,106,556 $2.23 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $345,646 - $846,832	172,823 Added 14.82%	1,339,186 $3.12 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $1.12 Million - $1.74 Million	240,918 Added 26.03%	1,166,363 $5.42 Million
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $732,937 - $1.09 Million	98,912 Added 11.97%	925,445 $7.06 Million
Q2 2021 Aug 16, 2021	BUY	$6.35 - $10.0 $188,487 - $296,830	29,683 Added 3.73%	826,533 $8.01 Million
Q1 2021 May 13, 2021	SELL	$7.03 - $16.51 $1.57 Million - $3.69 Million	-223,713 Reduced 21.92%	796,850 $6.59 Million
Q4 2020 Feb 09, 2021	BUY	$5.76 - $11.95 $1.46 Million - $3.03 Million	253,959 Added 33.13%	1,020,563 $6.97 Million
Q3 2020 Nov 05, 2020	BUY	$6.17 - $18.82 $1.01 Million - $3.09 Million	164,111 Added 27.24%	766,604 $8.55 Million
Q2 2020 Aug 13, 2020	BUY	$1.73 - $6.76 $920,403 - $3.6 Million	532,025 Added 754.99%	602,493 $3.78 Million
Q1 2020 May 14, 2020	BUY	$1.57 - $4.76 $110,634 - $335,427	70,468 New	70,468 $130,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.